Applied Therapeutics (APLT) Competitors $0.33 +0.01 (+4.79%) As of 01:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLT vs. SLS, GNFT, LRMR, CRGX, IMAB, CTMX, FDMT, OGI, EDIT, and DRUGShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include SELLAS Life Sciences Group (SLS), GENFIT (GNFT), Larimar Therapeutics (LRMR), CARGO Therapeutics (CRGX), I-Mab (IMAB), CytomX Therapeutics (CTMX), 4D Molecular Therapeutics (FDMT), Organigram Global (OGI), Editas Medicine (EDIT), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. Its Competitors SELLAS Life Sciences Group GENFIT Larimar Therapeutics CARGO Therapeutics I-Mab CytomX Therapeutics 4D Molecular Therapeutics Organigram Global Editas Medicine Bright Minds Biosciences SELLAS Life Sciences Group (NASDAQ:SLS) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Do insiders and institutionals believe in SLS or APLT? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 1.2% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer SLS or APLT? In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for SELLAS Life Sciences Group and 2 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.94 beat SELLAS Life Sciences Group's score of 0.63 indicating that Applied Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, SLS or APLT? SELLAS Life Sciences Group has higher revenue and earnings than Applied Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M210.04-$30.88M-$0.38-5.54Applied Therapeutics$460K100.34-$105.62M-$0.43-0.76 Which has more risk and volatility, SLS or APLT? SELLAS Life Sciences Group has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Is SLS or APLT more profitable? Applied Therapeutics' return on equity of -184.67% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -193.67% -113.02% Applied Therapeutics N/A -184.67%-84.02% Do analysts prefer SLS or APLT? Applied Therapeutics has a consensus price target of $6.10, indicating a potential upside of 1,771.17%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryApplied Therapeutics beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.16M$2.88B$5.52B$8.87BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-0.7621.6626.5019.82Price / Sales100.34267.10410.19110.66Price / CashN/A41.2925.8827.49Price / Book0.677.277.945.39Net Income-$105.62M-$55.05M$3.15B$248.34M7 Day Performance-0.73%-0.47%1.08%1.25%1 Month Performance-8.79%6.59%5.34%5.41%1 Year Performance-92.93%0.42%32.80%18.07% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics4.0359 of 5 stars$0.33+4.8%$6.10+1,771.2%-93.3%$46.16M$460K-0.7630SLSSELLAS Life Sciences Group0.3893 of 5 stars$1.93+4.1%N/A+84.0%$192.08M$1M-5.0710GNFTGENFIT2.2575 of 5 stars$3.83+6.1%$13.00+239.5%+3.2%$191.45M$76.77M0.00120Gap DownLRMRLarimar Therapeutics1.7165 of 5 stars$2.96-9.1%$18.50+526.1%-60.1%$190.17MN/A-1.9830CRGXCARGO Therapeutics2.5103 of 5 stars$4.09-1.2%$15.00+266.7%-74.9%$188.59MN/A-0.89116IMABI-Mab3.1396 of 5 stars$2.31-17.1%$5.50+138.6%+44.9%$188.23M$3.89M0.00380High Trading VolumeCTMXCytomX Therapeutics4.1819 of 5 stars$2.31+4.6%$5.33+130.8%+86.1%$187.76M$138.10M4.85170Positive NewsFDMT4D Molecular Therapeutics2.3034 of 5 stars$3.96-2.9%$29.56+645.8%-82.3%$183.88M$40K-1.25120OGIOrganigram Global1.1716 of 5 stars$1.37+3.4%N/A-12.3%$182.83M$117.47M13.65860EDITEditas Medicine4.2349 of 5 stars$2.11-3.9%$4.70+123.3%-52.9%$176.21M$32.31M-0.69230DRUGBright Minds Biosciences3.1994 of 5 stars$24.94-4.4%$83.25+233.8%+2,307.3%$175.58MN/A-69.28N/APositive NewsGap Down Related Companies and Tools Related Companies SELLAS Life Sciences Group Alternatives GENFIT Alternatives Larimar Therapeutics Alternatives CARGO Therapeutics Alternatives I-Mab Alternatives CytomX Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Organigram Global Alternatives Editas Medicine Alternatives Bright Minds Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLT) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
